MannKind Corporation must file a registration statement with the SEC, and FDA approval has triggered contingent value rights payment.
3 reports, 2 independent
Updated Jul 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MannKind Corporation must file a registration statement with the SEC, and FDA approval has triggered contingent value rights payment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.MannKind Corp. faces SEC filing requirements while FDA approval triggers financial payments.1 source
FDA approved Furoscix ReadyFlow injection for heart failure patients in the US.1 source
Keep exploring
The entities involved
-
MannKind Corporation
biopharmaceutical company
Nothing else this week.
- FDA
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- MannKind Corporation met with the FDA regarding its plan file for approval.
- 60 Degrees Pharmaceuticals, Inc. filed a registration statement with the Securities and Exchange Commission on July 17, 2025.
- A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- Litigation regarding FDA approval process.
Coverage
Newest first; wire copies grouped- manilatimes.net
- benzinga.comFDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M